Cellectis SA Cash Flow Conversion Efficiency
Cellectis SA cash flow conversion efficiency. Based on the latest financial reports, Cellectis SA (CLLS) has a cash flow conversion efficiency ratio of -0.348x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.28 Million) by net assets ($41.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cellectis SA (2007–2025)
Cash flow conversion efficiency of Cellectis SA from 2007 to 2025. This chart illustrates how Cellectis SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Cellectis SA for real-time trading data and today's change.
Cellectis SA Cash Flow Conversion Ratio Explained
Cellectis SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cellectis SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectis SA ranked by their cash flow conversion efficiency. Also see CLLS market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Emkay Global Financial Services Limited
NSE:EMKAY
|
-0.048x |
|
Eco World International Bhd
KLSE:5283
|
-0.054x |
|
Bullpen Parlay Acquisition Co
NASDAQ:BPAC
|
-0.005x |
|
MetaTech AP
TWO:3224
|
-0.013x |
|
Brightek Optoelectronic Co Ltd
TW:5244
|
-0.020x |
|
Groupe Minoteries SA
SW:GMI
|
0.015x |
|
Lifetime Brands Inc
NASDAQ:LCUT
|
-0.120x |
|
Adrad Holdings Ltd
AU:AHL
|
0.050x |
Annual Cash Flow Conversion Efficiency for Cellectis SA (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cellectis SA from 2007 to 2025. Review cash generation quality of Cellectis SA to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $75.90 Million | $-40.14 Million | -0.529x | -413.49% |
| 2024-12-31 | $131.03 Million | $22.10 Million | 0.169x | +157.73% |
| 2023-12-31 | $84.69 Million | $-24.75 Million | -0.292x | +57.92% |
| 2022-12-31 | $125.94 Million | $-87.44 Million | -0.694x | -57.03% |
| 2021-12-31 | $236.47 Million | $-104.56 Million | -0.442x | -70.15% |
| 2020-12-31 | $308.85 Million | $-80.26 Million | -0.260x | -33.61% |
| 2019-12-31 | $355.47 Million | $-69.14 Million | -0.195x | -28.54% |
| 2018-12-31 | $450.27 Million | $-68.14 Million | -0.151x | +17.32% |
| 2017-12-31 | $285.90 Million | $-52.33 Million | -0.183x | -61.34% |
| 2016-12-31 | $274.05 Million | $-31.09 Million | -0.113x | -1024.12% |
| 2015-12-31 | $288.22 Million | $3.54 Million | 0.012x | -98.25% |
| 2014-12-31 | $72.39 Million | $50.74 Million | 0.701x | +118.19% |
| 2013-12-31 | $6.65 Million | $-25.63 Million | -3.854x | -1105.67% |
| 2012-12-31 | $81.69 Million | $-26.11 Million | -0.320x | +10.29% |
| 2011-12-31 | $37.02 Million | $-13.19 Million | -0.356x | +15.35% |
| 2010-12-31 | $50.13 Million | $-21.10 Million | -0.421x | -337.25% |
| 2009-12-31 | $73.22 Million | $-7.05 Million | -0.096x | -350.06% |
| 2008-12-31 | $46.21 Million | $1.78 Million | 0.038x | +129.82% |
| 2007-12-31 | $43.54 Million | $-5.62 Million | -0.129x | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more